Bevacizumab

證據等級: L5

預測適應症: 10 個

Bevacizumab: From Multiple Solid Tumors to Epiglottis Neoplasm

One-Sentence Summary

Bevacizumab (Avastin) is a recombinant humanized anti-VEGF monoclonal antibody globally approved for multiple solid tumors — including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, glioblastoma, and ovarian cancer — working by blocking tumor angiogenesis. The TxGNN model predicts it may be effective for Epiglottis Neoplasm, with a prediction score of 99.90%. However, this specific indication is currently supported by 0 clinical trials and 0 publications, placing it at the lowest evidence tier (L5 — model prediction only), and a Hold decision is recommended at this time.

Quick Overview

Item	Content
Original Indication	Globally approved for multiple solid tumors (colorectal cancer, NSCLC, breast cancer, RCC, glioblastoma, ovarian/cervical cancer); not registered in Taiwan
Predicted New Indication	Epiglottis Neoplasm
TxGNN Prediction Score	99.90%
Evidence Level	L5 (model prediction only — no clinical or preclinical data)
Taiwan Market Status	✗ Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on information derivable from the evidence pack’s rationale annotations, Bevacizumab is a recombinant humanized monoclonal antibody that binds and neutralizes vascular endothelial growth factor A (VEGF-A), blocking its interaction with cell-surface receptors (VEGFR-1, VEGFR-2) on endothelial cells. This effectively suppresses the formation of new tumor vasculature, starving solid tumors of the oxygen and nutrients required for growth and metastasis. Its broad efficacy across VEGF-dependent solid tumors has been validated through global regulatory approvals in multiple jurisdictions.

Epiglottis neoplasms represent a heterogeneous disease category. Where the lesion is malignant — most commonly squamous cell carcinoma of the supraglottic larynx — VEGF-driven angiogenesis is well-documented in head and neck cancers broadly, providing a theoretical mechanistic basis for anti-VEGF intervention. This is the most plausible pathway by which TxGNN may have generated this prediction.

However, the critical caveat is that epiglottis neoplasms are most frequently benign (e.g., squamous papillomas, often HPV-associated). Benign lesions have fundamentally lower dependence on sustained pathological angiogenesis, and the risk-benefit calculation for systemic anti-VEGF therapy in a typically benign, surgically manageable condition is highly unfavorable. No preclinical or clinical data currently supports this specific application.

Clinical Trial Evidence

Currently no related clinical trials registered for Bevacizumab in epiglottis neoplasm.

Literature Evidence

Currently no related literature available for Bevacizumab in epiglottis neoplasm.

Cytotoxicity

Bevacizumab is a monoclonal antibody antineoplastic agent used in the treatment of solid malignancies; this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy — anti-VEGF monoclonal antibody (not a conventional cytotoxic agent)
Myelosuppression Risk	Low to moderate; neutropenia has been reported, though at significantly lower rates than conventional chemotherapy
Emetogenicity Classification	Low (biologics and monoclonal antibodies carry minimal emetogenic risk)
Monitoring Items	Blood pressure (clinically significant hypertension is a class effect), urine protein (risk of proteinuria/nephrotic syndrome), CBC with differential, coagulation parameters, wound healing assessment before elective surgery
Handling Protection	Standard biologic/monoclonal antibody handling procedures apply; not classified under conventional cytotoxic handling regulations, but institutional biosafety protocols for biologics should be followed

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert warnings, contraindications, and drug interaction data were not available in this evidence pack. Retrieval from the TFDA official website (package insert PDF parsing) is required before any clinical decision-making.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN computational score (99.90%), there is currently zero supporting clinical trial or published literature evidence for Bevacizumab in epiglottis neoplasm. The predominant benign nature of epiglottis lesions further undermines the biological rationale for systemic anti-VEGF therapy, making this a prediction that requires substantial scientific validation before any advancement.

To proceed, the following is needed:

Neoplasm characterization: Determine whether the target is a malignant lesion (e.g., squamous cell carcinoma of the epiglottis) or a benign lesion (e.g., papilloma); the answer fundamentally changes the risk-benefit profile and biological rationale
Preclinical evidence: Establish VEGF pathway dependence in epiglottis neoplasm tissue via in vitro or in vivo studies
MOA data retrieval: Query DrugBank API for complete pharmacological profile (per DG002 remediation plan)
Safety data retrieval: Download and parse TFDA package insert PDF for warnings and contraindications (per DG001 remediation plan, currently a Blocking data gap)
Cross-indication review: Consider whether evidence from higher-ranked multi-indication predictions in this pack (e.g., cystic neoplasm at rank 7 with a completed Phase 3 trial, NCT00565851, n=1,052) better represents Bevacizumab’s repurposing priority for Taiwan

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application. Data cutoff: 2026-04-05.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.